DCVax: Longer Survival Rates Without The Harsh Side Effects Of Standard Treatments

DCVax is an approach that utilizes a patient’s own dendritic cells and extracts of the patient’s own tumor cells to create a personalized treatment. I like this approach because patients who received DCVax showed a median survival of 3 years, with 33% of the patients alive at 4 yrs and 27% of the patients reaching or exceeding 6 yrs survival, compared with a median survival of only 14.6 months with standard treatment (surgery, radiation and chemotherapy).
Further Expansion of Clincal Trial Sites in Ongoing DCVax® immune therapy for Glioblastoma multiforme (GBM).

 


Speak Your Mind

*